Sponsors (26)
The bill strengthens infant-formula safety through quicker testing, reporting, and record retention — improving protection for babies — but risks higher costs, potential short-term supply disruptions, and implementation and confidentiality challenges for regulators and manufacturers.
Parents and infants: more frequent testing, uniform inspection standards, and faster mandatory reporting will improve detection and removal of contaminated infant formula, reducing the risk that unsafe product reaches babies.
Public health and oversight bodies: required retention of positive-test records and clear reporting chains will strengthen FDA inspections and investigations into contamination sources, aiding enforcement and future prevention.
Parents and infants (and purchasers): increased testing, recordkeeping, and rapid-reporting requirements will raise compliance costs for infant formula manufacturers that may be passed on to consumers as higher prices.
Parents and infants: stricter testing and fast-reporting could trigger more recalls or product holds, increasing the short-term risk of formula shortages or reduced availability.
FDA and health systems: a 90-day deadline for issuing final regulations may strain FDA resources and lead to rushed rulemaking or implementation problems that undermine effective enforcement.
Based on analysis of 2 sections of legislative text.
Directs FDA to require pathogen and environmental testing (including C. botulinum), rapid reporting, record retention, and uniform inspections for all infant formula, with final regs in 90 days.
Introduced March 9, 2026 by Rosa L. Delauro · Last progress March 9, 2026
Requires the FDA to update infant formula manufacturing rules to require pathogen and microorganism testing of facilities and finished products, including tests for Clostridium botulinum, specified environmental testing in production zones, one-business-day manufacturer notification to FDA of any positive result, and retention of positive-result records. It also directs FDA to apply consistent inspection and compliance standards to all infant formula regardless of country of origin and to issue final implementing regulations within 90 days; FDA must notify specified congressional committees within one business day of certain positive test results or adverse inspection findings.